AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16487668 — intervention group
Group type: COMPARATOR
Intervention: No prison methadone
Number of subjects: 0
Study 14723479 — intervention group
Group type: EXPERIMENTAL
Intervention: Active nicotine patch therapy (n = 2)
Number of subjects: 7
Study 14723479 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch therapy (n = 4)
Number of subjects: 7
Study 10753692 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons changed the gloves before the first contact with the vascular prosthesis (Group 1)
Number of subjects: 40
Study 10753692 — intervention group
Group type: COMPARATOR
Intervention: Operation without glove change (Group 2)
Number of subjects: 40
Study 9298322 — intervention group
Group type: EXPERIMENTAL
Intervention: Left visual field stimulation (LVF)
Number of subjects: 70
Study 9298322 — intervention group
Group type: EXPERIMENTAL
Intervention: Right visual field stimulation (RVF)
Number of subjects: 70
Study 9298322 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental goggles (LVF and RVF)
Number of subjects: 70
Study 9298322 — intervention group
Group type: COMPARATOR
Intervention: Control goggles (monocular vision)
Number of subjects: 70
Study 9298322 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental goggles
Number of subjects: 70
Study 8334003 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior pharyngeal constrictor myotomy
Number of subjects: 122
Study 8334003 — intervention group
Group type: COMPARATOR
Intervention: Herrmann technique
Number of subjects: 122
Study 8334003 — intervention group
Group type: COMPARATOR
Intervention: Classic total laryngectomy
Number of subjects: 122
Study 3089407 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient withdrawal programme
Number of subjects: 60
Study 3089407 — intervention group
Group type: COMPARATOR
Intervention: Outpatient withdrawal programme
Number of subjects: 60
Study 30276101 — intervention group
Group type: EXPERIMENTAL
Intervention: Interlaminar stabilization (ILS)
Number of subjects: 116
Study 30276101 — intervention group
Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 116
Study 27227406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (educational lectures, posters, pocket cards, computerized clinical decision support systems, electronic reminders)
Number of subjects: 1402
Study 27227406 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1402
Study 27227406 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 1402
Study 27227406 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1402
Study 25999980 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 55
Study 25999980 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 55
Study 25999980 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 55
Study 25999980 — intervention group
Group type: COMPARATOR
Intervention: Donepezil, Rivastigmine, Galantamine
Number of subjects: 55
Study 23290791 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole plus lithium or valproate
Number of subjects: 0
Study 23290791 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lithium or valproate
Number of subjects: 0
Study 20533241 — intervention group
Group type: EXPERIMENTAL
Intervention: GPLC (4.5 g/day)
Number of subjects: 15
Study 20533241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 19035097 — intervention group
Group type: EXPERIMENTAL
Intervention: Tones of 0.5, 2 or 4 kHz amplitude modulated (AM) sinusoidally at 8 Hz presented at 96 dB SPL
Number of subjects: 16
Study 16847171 — intervention group
Group type: EXPERIMENTAL
Intervention: GHK-Cu skin care products
Number of subjects: 13
Study 16847171 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GHK-Cu)
Number of subjects: 13
Study 14667955 — intervention group
Group type: EXPERIMENTAL
Intervention: Olopatadine
Number of subjects: 10
Study 14667955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 12050837 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation
Number of subjects: 311
Study 12050837 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 311
Study 12050837 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and music
Number of subjects: 311
Study 12050837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with interventions
Number of subjects: 311
Study 12050837 — intervention group
Group type: COMPARATOR
Intervention: Control group (PCA alone)
Number of subjects: 311
Study 10630656 — intervention group
Group type: EXPERIMENTAL
Intervention: Age adjusted warfarin loading protocol
Number of subjects: 186
Study 10630656 — intervention group
Group type: COMPARATOR
Intervention: Fennerty's protocol
Number of subjects: 186
Study 10630656 — intervention group
Group type: COMPARATOR
Intervention: Empirical dosing
Number of subjects: 186
Study 7604666 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori positivity
Number of subjects: 1180
Study 7604666 — intervention group
Group type: EXPERIMENTAL
Intervention: Age groups
Number of subjects: 1180
Study 7604666 — intervention group
Group type: COMPARATOR
Intervention: Ethnic background
Number of subjects: 1180
Study 1666684 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose naloxone (10 mg bolus plus 7 mg/hr)
Number of subjects: 8
Study 1666684 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 8
Study 6462107 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin alone (2 mg/kg IV)
Number of subjects: 12
Study 6462107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with carbenicillin (2 g IV every 8 h for six doses)
Number of subjects: 12
Study 6462107 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin with piperacillin (4 g IV every 12 h for four doses)
Number of subjects: 12
Study 3840740 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (4 mg preservative-free morphine in 6 ml saline)
Number of subjects: 20
Study 3840740 — intervention group
Group type: COMPARATOR
Intervention: Control group (anaesthetised without intrathecal morphine)
Number of subjects: 20
Study 29422049 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored intervention including clinician education, a specific website, and workshops for implementing cardiovascular guidelines.
Number of subjects: 43
Study 29422049 — intervention group
Group type: COMPARATOR
Intervention: Usual implementation of guidelines (by email, intranet, and clinical meetings).
Number of subjects: 43
Study 29422049 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored intervention.
Number of subjects: 43
Study 29422049 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted tailored intervention and usual implementation.
Number of subjects: 43
Study 27998224 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD1775 plus carboplatin
Number of subjects: 24
Study 25772920 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-wetting agent with 37% phosphoric acid etching
Number of subjects: 24
Study 25772920 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-wetting agent with Erbium: Yttrium aluminium garnet laser etching
Number of subjects: 24
Study 25772920 — intervention group
Group type: COMPARATOR
Intervention: Control group with 37% phosphoric acid etching
Number of subjects: 24
Study 25772920 — intervention group
Group type: COMPARATOR
Intervention: Control group with Erbium: Yttrium aluminium garnet laser etching
Number of subjects: 24
Study 23363041 — intervention group
Group type: EXPERIMENTAL
Intervention: Active e‐cigarette smoking
Number of subjects: 30
Study 23363041 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tobacco cigarette smoking
Number of subjects: 30
Study 23363041 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive e‐cigarette smoking
Number of subjects: 30
Study 23363041 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tobacco cigarette smoking
Number of subjects: 30
Study 21122094 — intervention group
Group type: EXPERIMENTAL
Intervention: Short leaflet
Number of subjects: 553
Study 21122094 — intervention group
Group type: EXPERIMENTAL
Intervention: Long leaflet
Number of subjects: 553
Study 21122094 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical information
Number of subjects: 553
Study 21122094 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagrams
Number of subjects: 553
Study 21122094 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender
Number of subjects: 553
Study 18691228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention (Risk evaluation/communication programme)
Number of subjects: 1103
Study 18691228 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1103
Study 18691228 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 1103
Study 16573545 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin induction, rapamycin (RAPA), and immunonutrients (arginine and omega-3 fatty acids); Mycophenolate mofetil (MMF) started in standard doses and discontinued by 2 years; CsA given in reduced doses for either 4, 6, or 12 months.
Number of subjects: 96
Study 14518801 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine interventions
Number of subjects: 1222
Study 14518801 — intervention group
Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 1222
Study 10715225 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorbitol 40 g/day in candy
Number of subjects: 66
Study 10715225 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 20 g/day in potato chips
Number of subjects: 66
Study 10715225 — intervention group
Group type: EXPERIMENTAL
Intervention: Olestra 40 g/day in potato chips
Number of subjects: 66
Study 10715225 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9177920 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 60
Study 9177920 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (DP)
Number of subjects: 60
Study 8268900 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine, possibly with a converting-enzyme inhibitor and a thiazide)
Number of subjects: 1395
Study 8268900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1395
Study 3082592 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms levonorgestrel + 50 micrograms ethinyloestradiol (LN 250 + EE 50)
Number of subjects: 0
Study 3082592 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 micrograms levonorgestrel + 30 micrograms ethinyloestradiol (LN 250 + EE 30)
Number of subjects: 0
Study 3082592 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg norethisterone acetate + 50 micrograms ethinyloestradiol (NA 1 + EE 50)
Number of subjects: 0
Study 28929486 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 146614
Study 26692079 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mechanical ventilation
Number of subjects: 171
Study 26692079 — intervention group
Group type: COMPARATOR
Intervention: High-frequency oscillation
Number of subjects: 171
Study 24397906 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM plus routine vaccines
Number of subjects: 7744
Study 24397906 — intervention group
Group type: COMPARATOR
Intervention: Routine vaccines alone
Number of subjects: 7744
Study 21549643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (CR)
Number of subjects: 112
Study 21549643 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study 20014980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation (ferric carboxymaltose)
Number of subjects: 0
Study 20014980 — intervention group
Group type: COMPARATOR
Intervention: Oral iron supplementation
Number of subjects: 0
Study 18544424 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 270 microg/kg rFVIIa
Number of subjects: 0
Study 18544424 — intervention group
Group type: COMPARATOR
Intervention: On-demand treatment schedules (multiple bolus doses of 90 to 120 microg/kg every 2 to 3 hours)
Number of subjects: 0
Study 15915415 — intervention group
Group type: EXPERIMENTAL
Intervention: ECUS-assisted technique
Number of subjects: 100
Study 15915415 — intervention group
Group type: COMPARATOR
Intervention: Traditional technique
Number of subjects: 100
Study 12514656 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary blood flow in CAE group
Number of subjects: 17
Study 12514656 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak hyperemic average peak velocities (APVs) of coronary blood flow in CAE group
Number of subjects: 17
Study 12514656 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric coronary blood flow at rest in CAE group
Number of subjects: 17
Study 12514656 — intervention group
Group type: EXPERIMENTAL
Intervention: Volumetric coronary blood flow at hyperemia in CAE group
Number of subjects: 17
Study 12514656 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean coronary flow reserve (CFR) in CAE group
Number of subjects: 17
Study 10907364 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients with complications (N1)
Number of subjects: 89
Study 10907364 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients without complications (N0)
Number of subjects: 89
Study 10907364 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (N0)
Number of subjects: 89
Study 9013369 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (60 mg administered orally)
Number of subjects: 6
Study 9013369 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analog pain ratings
Number of subjects: 6
Study 1568521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular rifamycin SV (525 mg/week) for 10 weeks
Number of subjects: 116
Study 1568521 — intervention group
Group type: COMPARATOR
Intervention: Auranofin (3 mg orally twice daily)
Number of subjects: 116
Study 1568521 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular rifamycin SV
Number of subjects: 116
Study 1568521 — intervention group
Group type: COMPARATOR
Intervention: Auranofin
Number of subjects: 116
Study 3883908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 19
Study 3883908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 31763263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasya Group
Number of subjects: 61
Study 31763263 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasya + Oral Group
Number of subjects: 61
Study 31763263 — intervention group
Group type: COMPARATOR
Intervention: Controlled Group
Number of subjects: 61
Study 28371482 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% brinzolamide/0.5% timolol fixed combination (BTFC)
Number of subjects: 201
Study 28371482 — intervention group
Group type: COMPARATOR
Intervention: 1% dorzolamide/0.5% timolol fixed combination (DTFC)
Number of subjects: 201
Study 25265147 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (1 μg/kg) and thiopental sodium (4 mg/kg)
Number of subjects: 120
Study 25265147 — intervention group
Group type: COMPARATOR
Intervention: Thiopental sodium (3 mg/kg, placebo)
Number of subjects: 120
Study 22234379 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) only
Number of subjects: 32
Study 22234379 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) before sessions 1 and 3, placebo (PBO) before session 2
Number of subjects: 32
Study 22234379 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) only
Number of subjects: 32
Study 21693655 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide with paclitaxel
Number of subjects: 3121
Study 21693655 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60, 75, or 90 mg/m²) and cyclophosphamide without paclitaxel
Number of subjects: 3121
Study 18269666 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group treated with the proposed surgical technique without releasing incisions
Number of subjects: 15
Study 18269666 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with a broader flap and vertical-releasing incisions
Number of subjects: 15
Study 17138264 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cognitive/sensorimotor stimulation program for infants, taught by public health nurses (PHNs) using the Curriculum and Monitoring System (CAMS).
Number of subjects: 62
Study 17138264 — intervention group
Group type: COMPARATOR
Intervention: State‐funded follow‐up program provided by the Los Angeles (LA) Regional Centers.
Number of subjects: 62
Study 17138264 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized cognitive/sensorimotor stimulation program for infants.
Number of subjects: 62
Study 12650957 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin (15 mg/day)
Number of subjects: 30
Study 12650957 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 11019421 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (15 g/day for 10 days)
Number of subjects: 42
Study 11019421 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 42
Study 8629674 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan, prednisone, and colchicine (MPC)
Number of subjects: 100
Study 8629674 — intervention group
Group type: COMPARATOR
Intervention: Colchicine (C)
Number of subjects: 100
Study 8629674 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC
Number of subjects: 100
Study 1420212 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐hr school‐based AIDS/HIV education program (n = 535)
Number of subjects: 1194
Study 1420212 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 659)
Number of subjects: 1194
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: MVP (mitomycin C, vinblastine, and cisplatin)
Number of subjects: 479
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: CBP (cyclophosphamide, bleomycin, and cisplatin)
Number of subjects: 479
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: AFP (doxorubicin, 5-fluorouracil, and cisplatin)
Number of subjects: 479
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: CAP (cyclophosphamide, doxorubicin, and cisplatin)
Number of subjects: 479
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rates for all regimens
Number of subjects: 479
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival by treatment
Number of subjects: 479
Study 3880810 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications of therapy
Number of subjects: 479
Study 31535359 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet rich plasma
Number of subjects: 30
Study 31535359 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 30
Study 29925515 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision Nutrition lifestyle program (12 months)
Number of subjects: 35
Study 29925515 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 27150644 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial opening of the inner hematoma membrane (group A)
Number of subjects: 52
Study 27150644 — intervention group
Group type: COMPARATOR
Intervention: No opening of the inner hematoma membrane (group B)
Number of subjects: 52
Study 23241505 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus LMI vaccine
Number of subjects: 21
Study 23241505 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 21
Study 22104057 — intervention group
Group type: COMPARATOR
Intervention: e-mail arm
Number of subjects: 51
Study 22104057 — intervention group
Group type: COMPARATOR
Intervention: lecture arm
Number of subjects: 51
Study 22104057 — intervention group
Group type: EXPERIMENTAL
Intervention: coaching arm
Number of subjects: 51
Study 18603261 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate treadmill exercise (70% of HR(max))
Number of subjects: 92
Study 18603261 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest
Number of subjects: 92
Study 17471790 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch (14 mg)
Number of subjects: 14
Study 17471790 — intervention group
Group type: EXPERIMENTAL
Intervention: Voucher-based reinforcement
Number of subjects: 14
Study 17471790 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both treatments
Number of subjects: 14
Study 15212838 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI) assessment of transverse relaxation rates (R2) in the genu (Gcc) and splenium (Scc) of the corpus callosum.
Number of subjects: 0
Study 15212838 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive measures such as R2.
Number of subjects: 0
Study 12377083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy with routine catheterization and revascularization as appropriate
Number of subjects: 2220
Study 12377083 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy with catheterization performed only for recurrent ischemia or a positive stress test
Number of subjects: 2220
Study 12377083 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy
Number of subjects: 2220
Study 12377083 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 2220
Study 9614518 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution ultrasound (Biovision B-Scan Probe)
Number of subjects: 20
Study 9614518 — intervention group
Group type: COMPARATOR
Intervention: Heidelberg Retinal Tomograph (HRT)
Number of subjects: 20
Study 9071621 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 125 mg orally twice daily for 4 weeks (Group 1, ages 5-15)
Number of subjects: 27
Study 9071621 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg orally twice daily for 4 weeks (Group 2, ages > 15)
Number of subjects: 27
Study 9071621 — intervention group
Group type: COMPARATOR
Intervention: Sodium stibogluconate intralesionally (for patients with partial cure or failure)
Number of subjects: 27
Study 2023034 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagraft
Number of subjects: 267
Study 2023034 — intervention group
Group type: COMPARATOR
Intervention: Cancellous iliac crest autograft
Number of subjects: 267